Trinity Delta Lighthouse: HUTCHMED
Trinity Delta view: Pipeline progress, coupled to commercial execution, is the key valuation driver for HUTCHMED. Recent solid news flow highlights the progress of key programmes that are set to deliver the new indications, new markets, and new products that we discussed in our December 2025 Update note. The start of clinical trials of the lead ATTC programme will focus investor, and potential partner, attention on this novel platform’s significant potential as it seeks to circumvent the toxicity limitations of ADCs. Our valuation for HUTCHMED is $5.98bn/£4.66bn/HK$46.61bn, or $34.26/ADS and 548p/HK$53.4 per share.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.